Proteomics International begins WA and NT rollout of PromarkerD and PromarkerEso with Healius
Proteomics International has begun the controlled commercial rollout of its PromarkerD and PromarkerEso blood tests in Western Australia and the Northern Territory through its exclusive pathology distribution agreement with Healius.
The rollout expands clinical access to PromarkerD, which assesses diabetic kidney disease risk, and PromarkerEso, which supports detection of oesophageal adenocarcinoma, ahead of a planned broader national launch.
The commercial milestone moves both tests further into routine pathology channels and represents an important step in Proteomics International's strategy to scale its diagnostic portfolio across Australia.
Field | Content |
Alert Type | Industry Update |
Companies | Proteomics International; Healius |
Development Type | Commercial rollout |
Products | PromarkerD; PromarkerEso |
Therapy Area(s) | Diabetes; kidney disease; oncology; oesophageal cancer |
Technology or Modality | Blood-based proteomic diagnostic tests |
Geography | Western Australia; Northern Territory; Australia |
What Happened | Proteomics International began the controlled market release of PromarkerD and PromarkerEso through Healius pathology services in Western Australia and the Northern Territory. |
Why It Matters | The rollout moves the tests from development and validation into broader clinical use through a major pathology network and provides a pathway toward national commercialisation. |
Supporting Context | PromarkerD is designed to assess risk of diabetic kidney disease progression, while PromarkerEso is a blood test intended to support detection of oesophageal adenocarcinoma. |
Strategic Rationale | The Healius distribution agreement gives Proteomics International access to established pathology infrastructure and a scalable channel for introducing its diagnostic products to clinicians and patients. |
Potential Impact | Wider clinical access could support earlier risk identification and diagnosis while generating real-world commercial and clinical evidence for both tests. |
Key Takeaway | Proteomics International has started commercial deployment of PromarkerD and PromarkerEso in WA and the NT through Healius ahead of a planned national rollout. |
What to Watch | Expansion into additional Australian states, clinician adoption and progress toward full national availability. |
Primary Source | Proteomics International |
Relevant Date | 14 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments